A Phase 1 interventional study of ARN-75039 in Healthy Volunteer and Pharmacokinetics After Oral Intake, sponsored by Arisan Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Arisan Therapeutics, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ARN-75039-103 is a comparative, randomized, single-dose, cross-over study to assess the PK, safety, and tolerability of neat ARN-75039 in hydroxypropyl methylcellulose (HPMC) capsules compared with ARN-75039 with excipients in tablet form, both administered orally, in healthy adult participants. The safety assessments will include standard evaluations of vital signs, clinical laboratory values, and ECGs.
Participants will be admitted to the study site on the morning of Day -1, before Period 1 study drug administration, and will remain on site until Day 15. Upon confirmation of eligibility, participants will be randomized into the study on Day 1. Study drug administration will be performed on the first day of Periods 1 and 2 (Study Days 1 and 8, respectively) with a 7-day washout period between the two periods. Participants will receive the randomized study drug in the morning following a meal. A total of 16 participants will be randomized 1:1 to the following two sequences:
Sequence 1:
Sequence 2:
Participation in the study will be conducted in the following 5 defined periods:
Participants who do not complete all study visits or terminate from the study before Day 15 will be asked to complete The Early Termination Visit is within 1 day after withdrawal from the study.
Two-period cross-over, Form A vs Form B, fed, inpatient Day -1 through Day 15, Day 36 follow-up
Arisan Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants meeting all the following criteria are eligible for study participation:
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible for study participation:
History of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational antiviral agent (300 mg neat ARN-75039 in HPMC capsules) administered as a single oral dose for pharmacokinetic evaluation.
Drug: ARN-75039
Investigational antiviral agent (3x100 mg ARN-75039 tablet with excipients) administered as a single oral dose for pharmacokinetic evaluation.
Drug: ARN-75039
An oral therapy for the treatment of Lassa infection
AUC0-t
Area Under the Plasma-drug Concentration Time Curve from time zero to time of last quantifiable concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
Time frame: From time zero (dose) to time of last quantifiable concentration. Period 1: 0 to 144 hours; Period 2: 0 to 168 hours.
AUC0-24
Area under the plasma concentration-time curve from time zero to 24 hours post-dose. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
Time frame: From time zero (dose) to 24 hours post-dose.
AUC0-∞
Area under plasma concentration-time curve from time zero to infinity. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
Time frame: From time zero (dose) extrapolated to infinity. Time frame is from 0 to Tlast + extrapolation from C last to infinity time, where concentration is equal to 0.
Cmax
Maximum observed plasma concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
Time frame: From time 0 (dose) through 168 hours post-dose.
Tmax
Time to reach Cmax
Time frame: From time 0 (dose) through 168 hours post-dose.
t1/2
Half-life
Time frame: From time 0 (dose) through 168 hours post-dose (terminal elimination phase).
CL/F
Apparent clearance after extravascular administration.
Time frame: From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).
Vz/F
Apparent volume of distribution during the terminal phase after extravascular administration.
Time frame: From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).
Participants With ≥1 TEAE
Type and frequency of treatment-emergent adverse events (TEAEs).
Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Participants With ≥1 TESAE
Type and frequency of treatment-emergent serious adverse events (TESAEs).
Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Participants With Study Drug-related TEAEs of Grade >1
Type and frequency of study drug-related \>Grade 1 TEAEs
Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Sixteen participants were enrolled, and none discontinued the study early or were excluded from analysis. All the informed consent forms (ICFs) were signed within the window from February 27, 2025 and March 11, 2025.
| Milestone | Sequence 1: Form A (Capsule), Then Form B (Tablet) | Sequence 2: Form B (Tablet), Then Form A (Capsule) |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: Form A (Capsule), Then Form B (Tablet) | Sequence 2: Form B (Tablet), Then Form A (Capsule) |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: Form A (Capsule), Then Form B (Tablet) | Sequence 2: Form B (Tablet), Then Form A (Capsule) |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Area Under the Plasma-drug Concentration Time Curve from time zero to time of last quantifiable concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
| h*ng/ml | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| AUC0-t | 9450 ± 3230 | 8990 ± 3060 |
Area under the plasma concentration-time curve from time zero to 24 hours post-dose. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
| h*ng/ml | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| AUC0-24 | 6150 ± 2120 | 5820 ± 1980 |
Area under plasma concentration-time curve from time zero to infinity. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
| h*ng/ml | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| AUC0-∞ | 11800 ± 2570 | 9700 ± 2770 |
Maximum observed plasma concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.
| ng/ml | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Cmax | 847 ± 266 | 828 ± 226 |
Time to reach Cmax
| h | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Tmax | 4 ± 2-6 | 3.5 ± 2-4.1 |
Half-life
| h | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| t1/2 | 141 ± 52.4 | 120 ± 49.1 |
Apparent clearance after extravascular administration.
| L/h | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| CL/F | 26.4 ± 5.99 | 35 ± 17.1 |
Apparent volume of distribution during the terminal phase after extravascular administration.
| L | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Vz/F | 3820 ± 1290 | 4810 ± 2270 |
Type and frequency of treatment-emergent adverse events (TEAEs).
| Participant count | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Participants With ≥1 TEAE | 0 | 3 |
Type and frequency of treatment-emergent serious adverse events (TESAEs).
| Participant count | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Participants With ≥1 TESAE | 0 | 0 |
Type and frequency of study drug-related \>Grade 1 TEAEs
| Participant count | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Participants With Study Drug-related TEAEs of Grade >1 | 0 | 0 |
Collected over From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARN-75039 Form A (HPMC Capsule) | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| ARN-75039 Form B (Tablet With Excipients) | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Event | ARN-75039 Form A (HPMC Capsule) | ARN-75039 Form B (Tablet With Excipients) |
|---|---|---|
| Sinus tachycardiaCardiac disorders | 0/16 | 1/16 |
| HeadacheNervous system disorders | 0/16 | 1/16 |
| Rash macularSkin and subcutaneous tissue disorders | 0/16 | 1/16 |
Safety/PK population: all randomized participants who received at least 1 dose of study drug. In the cross-over design, results are presented per intervention (Form A vs Form B) by pooling all participants exposed to each intervention across periods/sequences; participants contribute data to both arms. Events are attributed to the treatment received at onset; events during washout are attributed to the prior treatment.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 37.7 ± 5.96 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 7 |
| Male | 9 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 12 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Weight(kg) | All Participants |
|---|---|
| Mean | 74.1 ± 9.96 |
| Height(cm) | All Participants |
|---|---|
| Mean | 167.8 ± 7.48 |
| Body Mass Index (BMI)(kg/m^2) | All Participants |
|---|---|
| Mean | 26.4 ± 3.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2025 to primary completion in Apr 2025, 1 month.
Results were first posted in May 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARN-75039
Arisan Therapeutics, Inc.